PharmaSource’s Post

This week, we are kicking off our first March tradeshow in 2024! Biologics 2024 is around the corner, and our team members Tim Nieters and Andrew Kennedy will be on site at booth #53 to answer any questions for your peptide and oligonucleotide projects. As a sponsor for Biologics 2024, we are a leader in GMP manufacturing and comprehensive CRDMO services for synthetic peptide and oligonucleotide production. With over two decades of dedicated service to the pharmaceutical industry, CPC Scientific has emerged as a trusted provider of high-quality products, supporting researchers and companies globally. CPC Scientific's legacy includes hundreds of projects in clinical development and 10 successful commercial projects worldwide. Notably, in the upcoming year, CPC Scientific is set to enhance the pharmaceutical supply chain's resilience in the United States with the opening of our California GMP facility, ensuring the secure availability of critical therapeutic APIs. View the full agenda: https://hubs.la/Q02ljQtL0 #Biologics24 #OGBiologics #CPCScientific #GMPManufacturing #CRDMO #PharmaceuticalIndustry #TherapeuticDevelopment #Innovation

📈 Evolution of CDMOs’ role : SyrHA listens to its customers and pharmaceutical companies. We can see that the expectations of biopharmaceutical customers are increasing.   CDMOs are looking to expand their capabilities and enrich their services to support their customers from one end of the chain to the other.   Could we see the emergence of CRDMOs, merging services provided by CROs, CDOs, CMOs and CPOs, which were historically fragmented ? 🧐   Come and see how SyrHA supports its customers ! 👇 Read the rest of the article : 🔗 https://lnkd.in/edTeQyms

One of the companies to pitch at the 2024 Biotech Hanse Forum #BTHF2024 will be #DoubleBondPharmaceutical, represented by Kristel Parv Kinsella, PhD. "Our mission is to provide patients with more efficient and safer products in areas where their needs are not met. We focus on the development of innovative drug delivery systems designed to reduce side effects and improve efficacy. Our flagship product is SI-053, which is a new gel formulation containing temozolomide for local treatment of Grade IV glioblastoma". Why did the company choose to participate in the BTHF and what are the expectations?  "Participating in the Biotech-Hanse Forum gives us the opportunity to raise awareness about Double Bond Pharmaceutical, and more importantly, our drug development efforts in the glioblastoma field and to meet new potential partners for the development of our pipeline". We are looking forward to meeting you at the Forum on June 18th, Kristel!

As the 2024 PDA - Parenteral Drug Association Annual Meeting is rapidly approaching, we at Lindström are thrilled to announce our sponsorship of this esteemed event. Our commitment to innovation and excellence in the pharmaceutical industry aligns perfectly with the PDA's mission to advance pharmaceutical and biopharmaceutical technology globally. We are eagerly anticipating the opportunity to connect with delegates, attendees, and fellow industry professionals. Our team will be on hand to discuss the latest trends, share insights, and explore how Lindström's solutions can support the critical work being done across the parenteral drug sector. #pdac2024 #contaminationcontrol #usfda #cleanroomlaundry Manas KumarRamdev AgarwalJayant Roy #regulatorycompliance #gmpcompliance #annex1

Super excited for this panel discussion at #ChemOutsourcing2024! We’ll dive into the global pharma market, balancing regional needs, and navigating pricing pressures. Can't wait to hear the insights from industry leaders. This is a discussion you won't want to miss.

🚀 New drug approvals April-May 2024   Stay ahead of the curve with our latest update on FDA and EMA drug approvals.   FDA and EMA have recently approved several new drugs, driving forward the industry’s commitment to innovative healthcare solutions. Recent approvals: 👉 FDA: Imdeltra Amgen, Xolremdi X4 Pharmaceuticals, Ojemda Day One Biopharmaceuticals, Anktiva Altor Bioscience Corporation, Lumisight Lumicell, Zevtera Basilea Pharmaceutica 👉 EMA: Adzynma Takeda, Akantior SIFI, Cejemly SFL Pharma, Durveqtix Pfizer, Fluenz AstraZeneca, Ixchiq Valneva, Zegalogue Zealand Pharma   We've highlighted 4 standout drugs to better understand how they compare with available treatments: Xolremdi, Anktiva, Zevtera, and Cejemly.   Interested in more information on future launches? Sign up to be the first to receive the updates. #drugapprovals #fda #ema #pharma #pharmaceuticals #biotech #takeda #pfizer #astrazeneca #amgen #lumicell  #ZealandPharma #ValnevaAustria #SIFISPA #SFLPharmaceuticals #x4Pharmaceuticals #DayOnePharmaceuticals #bacilea

The future of cannabinoid-based pharmaceutical products looks bright as more countries open doors to the research and development behind these molecules. To explore what lies ahead, our partner in cannabinoid innovation, Brains Bio, hosted a panel discussion at the International Cannabis Business Conference (ICBC) in Berlin. The panel brought together experts in the cannabinoid field, including Athanasia Kanli (Global Market Development Manager), to discuss the future of cannabinoid-based pharmaceutical research and product development. Join the discussion and watch the panel discussion on-demand: https://lnkd.in/ew863YMY #cannabinoids #cannabidiol #APIs #pharmaceuticals #drugdevelopment

https://lnkd.in/gGNcTv8Q - A cleaning validation study involves testing manufacturing surfaces to ensure that they are being cleaned to an acceptable level of residue, documenting that testing data, and establishing procedures to maintain that level of cleanliness. Explore the steps involved in cleaning validation and what it provides for manufacturers. #pharma #biopharmaceutical #cleaningvalidation #rna #riskmitigation #contaminationcontrol #detergents Alconox Inc., Jeff Phillips, Michael Moussourakis, Elliot Lebowitz, Pharmaceutical Online Bristol Myers Squibb, Teva Pharmaceuticals, Pfizer, Eli Lilly and Company, Novo Nordisk, Novartis, Amgen, Thermo Fisher Scientific, Catalent Pharma Solutions, Lonza, Regeneron, Kite Pharma, Spark Therapeutics, Inc., Bayer, Gilead Sciences, PCI Pharma Services, Zoetis, Simtra BioPharma Solutions, The Ritedose Corporation

India’s pharmaceutical industry is currently ranked third globally for pharmaceutical production by volume and 14th by value. The country has a well-established domestic pharmaceutical industry, featuring a network of around 3,000 drug companies and approximately 10,500 manufacturing units. The future of this industry appears promising, with the Indian pharmaceutical products market projected to achieve a value of approximately US$130 billion by the end of 2030. Concurrently, the global pharmaceutical products market is expected to surpass the US$1 trillion mark in 2024

https://lnkd.in/eBKnC-WX GSK is buying biopharmaceutical company Aiolos Bio for up to $1.4 billion in a deal that expands its respiratory pipeline and follows a string of pharmaceutical majors buying fast-growing biotechs to restock their pipelines. Aiolos Bio focuses on patients with respiratory and inflammatory conditions, includes a Phase 2-ready antibody called AIO-001 for the treatment of adult patients with certain respiratory and inflammatory conditions. #asthmadrugs